Rxsight Inc - Asset Resilience Ratio
Rxsight Inc (RXST) has an Asset Resilience Ratio of 65.89% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check RXST capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Rxsight Inc's Asset Resilience Ratio has changed over time. See RXST equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Rxsight Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RXST market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $200.31 Million | 65.89% |
| Total Liquid Assets | $200.31 Million | 65.89% |
Asset Resilience Insights
- Very High Liquidity: Rxsight Inc maintains exceptional liquid asset reserves at 65.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rxsight Inc Industry Peers by Asset Resilience Ratio
Compare Rxsight Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Rxsight Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Rxsight Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.76% | $208.18 Million | $311.81 Million | -2.46pp |
| 2024-12-31 | 69.22% | $220.52 Million | $318.56 Million | +4.86pp |
| 2023-12-31 | 64.36% | $117.49 Million | $182.55 Million | +1.78pp |
| 2022-12-31 | 62.58% | $93.97 Million | $150.16 Million | -7.46pp |
| 2021-12-31 | 70.03% | $134.97 Million | $192.72 Million | +15.42pp |
| 2020-12-31 | 54.61% | $54.98 Million | $100.68 Million | -11.23pp |
| 2019-12-31 | 65.84% | $72.71 Million | $110.43 Million | -- |
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more